Monty Rakusen Background In business since 1954 as a division of Eli Lilly (LLY), Elanco Animal Health (NYSE:ELAN) was spun off as an independent public company in 2018. In the animal health space, Elanco is second by revenue, behind leader Zoetis (ZTS), with roughly half the revenue of Zoetis. Zoetis was spun off from Pfizer in 2012. Jeffrey N. Simmons has been President and CEO of Elanco since the spinoff from Eli Lilly. On August 1, 2020, Elanco purchased Bayer Animal Health in a deal valued at $6.89 bil ...